Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Cash: 2014-2025

Historic Change in Cash for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to $66.5 million.

  • Viking Therapeutics' Change in Cash rose 929.28% to $66.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year increase of 280.10%. This contributed to the annual value of -$28.7 million for FY2024, which is 251.70% down from last year.
  • Latest data reveals that Viking Therapeutics reported Change in Cash of $66.5 million as of Q3 2025, which was up 1,742.84% from -$4.0 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Change in Cash registered a high of $140.1 million during Q1 2024, and its lowest value of -$151.7 million during Q2 2024.
  • Over the past 3 years, Viking Therapeutics' median Change in Cash value was $6.5 million (recorded in 2024), while the average stood at $5.8 million.
  • Per our database at Business Quant, Viking Therapeutics' Change in Cash skyrocketed by 1,195.85% in 2023 and then slumped by 396.46% in 2024.
  • Viking Therapeutics' Change in Cash (Quarterly) stood at $15.1 million in 2021, then slumped by 53.11% to $7.1 million in 2022, then spiked by 158.10% to $18.3 million in 2023, then plummeted by 229.08% to -$23.6 million in 2024, then soared by 929.28% to $66.5 million in 2025.
  • Its Change in Cash stands at $66.5 million for Q3 2025, versus -$4.0 million for Q2 2025 and $11.3 million for Q1 2025.